A team of scientists from government, academia and private industry has developed a novel treatment that protects mice from infection with the bacterium that causes tularemia, a highly infectious disease of rodents, sometimes transmitted to people, and also known as rabbit fever.
In additional experiments with human immune cells, the treatment also demonstrated protection against three other types of disease-causing bacteria that, like the tularemia bacteria, occur naturally, can be highly virulent, and are considered possible agents of bioterrorism.
The experimental therapeutic works by stimulating the host immune system to destroy invading microbes. In contrast, antibiotics work by directly attacking invading bacteria, which often develop resistance to these medications. The therapeutic has the potential to enhance the action of antibiotics and provide an alternative to them.
"A therapeutic that protects against a wide array of bacterial pathogens would have enormous medical and public health implications for naturally occurring infections and potential agents of bioterrorism," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. "This creative approach is a prime example of public-private partnerships that can facilitate progress from a basic research finding to new, desperately needed novel therapeutics."
Catharine Bosio, Ph.D., and her colleagues at NIAID's Rocky Mountain Laboratories in Hamilton, Mont., led the study. Study collaborators are from Colorado State University in Fort Collins and Juvaris Biotherapeutics of Burlingame, Calif. The study is available online in the open-access journal PLoS Pathogens.
In the study, the researchers combined components isolated from the membrane of a weakened strain of Francisella tularensis, the agent of tularemia, with the Juvaris product CLDC (cationic liposome DNA complexes). The combination stimulated a natural antibacterial mechanism, called reactive oxygen species (ROS) and reactive nitrogen species (RNS), in immune cells that ingest bacteria. ROS and RNS attack and kill invading bacteria, preventing replication and spread of the pathogens to other cells.
Sixty percent of mice in the study survived lethal pulmonary infection with virulent F. tularensis when treated with the therapeutic intravenously three days before the bacterial challenge. No mice survived when given the bacterial components or the CLDC alone, demonstrating the importance of combining both to maximize protection in mouse and human cells. The treatment also showed broad usage, protecting human immune cells from bacteria that cause plague, melioidosis and brucellosis as well as tularemia. Melioidosis is primarily a tropical disease spread to humans and animals through contaminated soil and water. Brucellosis is a disease that primarily affects animals, including humans who come in contact with infected animals or animal products, such as contaminated milk.
According to Dr. Bosio, the three-day advance treatment appears crucial to providing enough time to stimulate the immune system. Any treatment less than three days in advance failed to protect the mice, she said.
"We are continuing to improve the versatility of this treatment as an antibacterial therapeutic with respect to timing of delivery and efficacy," she says. "Meanwhile, CLDC plus membrane protein fractions is proving to be an excellent tool to determine how to safely and successfully stimulate the body's own antibacterial army to protect itself against highly infectious invaders."
The research team will continue to study the precise role that membrane protein fractions play in combination with CLDC, and how the combination affects the production of RNS and ROS in cells from mice and from humans.
For more information, visit NIAID' Tularemia Web page at http://www.niaid.nih.gov/topics/tularemia/Pages/research.aspx.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
Reference: R Ireland et al. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathogens 6(5): e1000921. DOI:10.1371/journal.ppat.1000921 (2010).
Ken Pekoc | EurekAlert!
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration
"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...
Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.
Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
16.01.2017 | Trade Fair News
16.01.2017 | Automotive Engineering
16.01.2017 | Life Sciences